Christine Zedelmayer Sells 9,821 Shares of Equillium (NASDAQ:EQ) Stock

Key Points

• Equillium COO Christine Zedelmayer sold 9,821 shares on May 27 at an average price of $2.70, reducing her direct ownership by 13.56%. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
• Insider selling has been active, with Zedelmayer also selling additional large blocks of Equillium stock in recent days and months. The article notes another insider, Penny Tom, also sold shares, which may weigh on investor sentiment.
• Analysts remain broadly positive on EQ, with recent upgrades and price targets including Leerink Partners raising the stock to outperform with a $6 target and Raymond James reiterating a strong-buy rating with a $7 target. MarketBeat reports a consensus rating of Moderate Buy and an average price target of $7.57.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 9,821 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $2.70, for a total value of $26,516.70. Following the sale, the chief operating officer directly owned 62,586 shares of the company's stock, valued at $168,982.20. The trade was a 13.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The stock was sold at an average price of $2.80, for a total value of $240,833.60.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Stock Performance

Equillium stock traded up $0.06 during mid-day trading on Friday, reaching $2.90. 853,917 shares of the company were exchanged, compared to its average volume of 480,896. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $3.10. The firm's 50-day simple moving average is $2.09 and its two-hundred day simple moving average is $1.63. The firm has a market cap of $183.37 million, a PE ratio of -9.06 and a beta of 1.67.

Equillium (NASDAQ:EQ - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). As a group, equities research analysts anticipate that Equillium, Inc. will post -0.24 EPS for the current year.

Analysts Set New Price Targets

EQ has been the subject of several recent analyst reports. Raymond James Financial reissued a "strong-buy" rating and issued a $7.00 price target on shares of Equillium in a report on Thursday. Leerink Partners raised Equillium from a "market perform" rating to an "outperform" rating and raised their price target for the company from $1.00 to $6.00 in a report on Thursday. Zacks Research raised Equillium to a "hold" rating in a research note on Thursday, February 26th. Cantor Fitzgerald began coverage on Equillium in a research note on Tuesday, April 7th. They issued an "overweight" rating and a $10.00 price objective for the company. Finally, Stifel Nicolaus set a $5.00 price objective on Equillium in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $7.57.

Institutional Investors Weigh In On Equillium

Several hedge funds have recently made changes to their positions in EQ. Dimensional Fund Advisors LP acquired a new position in shares of Equillium during the first quarter worth about $31,000. Virtu Financial LLC lifted its stake in shares of Equillium by 133.4% during the third quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock worth $34,000 after purchasing an additional 13,591 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Equillium during the third quarter worth about $35,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Equillium during the first quarter worth about $100,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Equillium during the third quarter worth about $99,000. Institutional investors and hedge funds own 27.05% of the company's stock.

Equillium News Roundup

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

About Equillium

Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.